(Q58073798)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21963091%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

The importance of chemotherapy and radiation in uterine papillary serous carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21963091%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21963091%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Eric A Macklin

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21963091%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

4

Ursula Matulonis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21963091%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Ross Berkowitz

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21963091%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

language of work or name

English

0 references

publication date

2 October 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21963091%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21963091%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

123

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21963091%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21963091%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

542-547

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21963091%20AND%20SRC:MED&resulttype=core&format=json

Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium.

13 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Adenocarcinoma of the endometrium. Analysis of 256 cases with disease limited to the uterine corpus: treatment comparisons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Adjuvant whole-abdominal radiation therapy in uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Uterine papillary serous carcinoma. A clinical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Early stage uterine papillary serous carcinoma of the endometrium: effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Long-term survival with adjuvant whole abdominopelvic irradiation for uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Outcome and pattern of failure in pathologic stage I–II papillary serous carcinoma of the endometrium: Implications for adjuvant radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

High-dose rate brachytherapy for Stage I/II papillary serous or clear cell endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

The role of radiotherapy in the management of resected uterine papillary serous and clear cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Twelve-year experience in the management of endometrial cancer: a change in surgical and postoperative radiation approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

A new aggressive treatment approach to high-grade endometrial cancer of possible benefit to patients with stage I uterine papillary cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Adjuvant therapy for patients with stage I papillary serous endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Outcomes in surgical stage I uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Uterine papillary serous carcinoma: evaluation of multimodality treatment with abdominopelvic radiotherapy and chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

A Proportional Hazards Model for the Subdistribution of a Competing Risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Treatment of uterine papillary serous carcinoma with paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

The role of abdominal-pelvic radiotherapy in the management of uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Improved outcome at 10 years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005

Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.005